‘Inactive’ Label Doesn’t Make Cannabinoids Less Active Or Clear Their Use In OTC Drugs In US
FDA warns BioLyte Laboratories and Honest Globe about making OTC drugs with cannabinoids. Firms also advised about GMP problems and that labeling cannabinoids as inactive ingredients doesn’t make their use compliant.
You may also be interested in...
GMP warnings to firms making supplement firms marketed in US have been rare since FDA temporarily suspended on-site inspections with onset of COVID-19 pandemic. But GMP problems surfaced after agency resumed inspections last July.
VMS firm Ambrosia-SupHerb partners with cannabis product developer Tikun-Olam to create Israel’s first cannabis and mushroom supplement line.
Nasadol CBD Nasal Sprays not only are violative for claims unallowed for CBD, but for containing CBD. FDA also warns online pharmacy about fraudulent OTC COVID-19 cure kit.